Scholarlink

<p>Tissue biodistribution characterization represents a critical component of monoclonal antibody (mAb) development, yet industry practices remain fragmented despite regulatory emphasis on comprehensive exposure assessment. The IQ Consortium Tissue Concentration Working Group surveyed eleven pharmaceutical companies to evaluate current methodologies in mAb tissue concentration analysis and establish consensus recommendations. Organizations demonstrated heterogeneous portfolio compositions, with traditional monospecific IgG1 and IgG4 platforms dominating 81.8% of companies while next-generation multispecific formats and antibody–drug conjugates gained prominence. Strategic approaches to biodistribution evaluation differed markedly, as 72.7% implemented compound-dependent assessment protocols <i>versus</i> systematic screening paradigms. Peak measurement activity occurred during lead optimization phases (63.6%) and pre-clinical candidate advancement (54.5%), reflecting resource optimization rather than mechanistic investigation priorities. Universal adoption of ligand binding methodologies complemented mass spectrometry integration in 81.8% of programs, though analytical validation standards exhibited substantial inconsistency. Blood contamination correction procedures were systematically implemented by merely 18.2% of respondents, indicating widespread methodological gaps. While tissue concentration datasets informed translational pharmacokinetic modeling across 81.8% of organizations, physiologically-based modeling frameworks remained underutilized. Results underscore urgent requirements for analytical harmonization to strengthen regulatory submissions and accelerate therapeutic development timelines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Industry Practices in Monoclonal Antibody Tissue Biodistribution Assessment: An IQ Consortium Cross-Industry Survey of Current Approaches and Emerging Trends

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Huaping Tang,
  • Michael McCoy,
  • Antony Leonard,
  • Krithika Mohan,
  • Ramola Sane,
  • Chi Guan,
  • Majlinda Kullolli Thomas,
  • Katharina Koep

摘要

Tissue biodistribution characterization represents a critical component of monoclonal antibody (mAb) development, yet industry practices remain fragmented despite regulatory emphasis on comprehensive exposure assessment. The IQ Consortium Tissue Concentration Working Group surveyed eleven pharmaceutical companies to evaluate current methodologies in mAb tissue concentration analysis and establish consensus recommendations. Organizations demonstrated heterogeneous portfolio compositions, with traditional monospecific IgG1 and IgG4 platforms dominating 81.8% of companies while next-generation multispecific formats and antibody–drug conjugates gained prominence. Strategic approaches to biodistribution evaluation differed markedly, as 72.7% implemented compound-dependent assessment protocols versus systematic screening paradigms. Peak measurement activity occurred during lead optimization phases (63.6%) and pre-clinical candidate advancement (54.5%), reflecting resource optimization rather than mechanistic investigation priorities. Universal adoption of ligand binding methodologies complemented mass spectrometry integration in 81.8% of programs, though analytical validation standards exhibited substantial inconsistency. Blood contamination correction procedures were systematically implemented by merely 18.2% of respondents, indicating widespread methodological gaps. While tissue concentration datasets informed translational pharmacokinetic modeling across 81.8% of organizations, physiologically-based modeling frameworks remained underutilized. Results underscore urgent requirements for analytical harmonization to strengthen regulatory submissions and accelerate therapeutic development timelines.